WHAT DOES THIS MEAN FOR PATIENTS? {#sec11}
=================================

Gonadotrophins are injectable drugs that are used to stimulate oocyte growth as part of IVF treatment. Three types of gonadotrophins are used most frequently: urinary-derived FSH, human menopausal gonadotrophin and recombinant FSH. These gonadotrophins are known to be equally effective and safe but it is unknown whether they differ in required amount. Hence, a literature review was performed to evaluate whether the three gonadotrophins differ in amount required to achieve a pregnancy leading to the birth of a child. The authors found no substantial differences in required amount between the gonadotrophins. It is concluded that the gynecologists should choose the hormone based on convenience, availability, actual costs and patient preferences.

Introduction {#sec12}
============

Ovarian stimulation with gonadotrophins to induce the development of multiple follicles is the first phase of most ART ([@ref31]). At present, gynecologists can choose between three commercially available gonadotrophins for ovarian stimulation in IVF/ICSI: rFSH, highly purified (HP)-hMG and HP-FSH.

Recombinant FSH (rFSH) is manufactured by recombinant DNA technology using a Chinese hamster ovary cell line transfected with the genes encoding human FSH (follitropin a and follitropin b) or derived from a cell line of human fetal retinal origin (FE 999049). It has 99% purity, does not contain any LH activity and is very similar to natural FSH ([@ref36]; [@ref35]). HP urinary gonadotrophins (HP-hMG and HP-FSH) are derived from urine of postmenopausal women. HP-hMG contains \<5% of co-purified proteins and a 1:1 ratio of FSH and LH bioactivity and due to purification steps HP-FSH contains \<0.1 IU LH and \<5% of co-purified proteins ([@ref30]; [@ref42]).

The various gonadotrophin products are heterogeneous in isoform composition. The urinary preparations have more acidic isoforms compared to the recombinant products ([@ref28]). Basic FSH isoforms have a high receptor affinity *in vitro* and a short half-life *in vivo* compared to acidic FSH isoforms ([@ref37]). It has been suggested that due to the lower acidity rFSH might be more biopotent *in vivo* and that, as a consequence, a lower total dose and less stimulation days compared to highly purified urinary-derived gonadotrophins would be required ([@ref4]).

It has been widely discussed in the literature that the differences in live birth between gonadotrophins are limited. What we were interested in is their economic value. The actual cost in euros or dollars differs widely between countries and therefore our focus was on the resource use that determines eventual cost differences. This resource use was expressed as amount of IU used. Therefore, we systematically examined the evidence on the total amount of recombinant and highly purified urinary-derived gonadotropins required to reach a live birth after ovarian stimulation in couples undergoing IVF or ICSI treatment.

Materials and Methods {#sec13}
=====================

The review is reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The protocol for this systematic review is registered in the Prospective Register of Systematic Reviews (PROSPERO) in April 2016 (Registration: Prospero CRD42016038238, available from <http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016038238>).

Literature search {#sec14}
-----------------

We conducted a literature search in the databases Medline, Embase and CINAHL up to July 2018. We used the same search terms as the Cochrane review on the effectiveness of recombinant FSH versus urinary-derived gonadotrophins ([@ref41]) ([Supplementary data](#sup1){ref-type="supplementary-material"}).

Inclusion criteria and study selection {#sec15}
--------------------------------------

We screened all records for eligibility by analyzing the title and abstract. We included randomized controlled trials comparing rFSH with HP-hMG or HP-FSH for ovarian stimulation in couples with an indication for IVF or ICSI treatment. We excluded studies that compared rFSH with hMG or pituitary extract-FSH, because these products are no longer available for ovarian stimulation. There was no language restriction. After the eligibility screening we analyzed the studies by reading the full text. The studies were selected by two reviewers (E.B. and M.W.).

Data extraction and outcomes {#sec16}
----------------------------

We extracted data on female age, previous ART cycles, the number of women in each study arm, intervention details such as agonist or antagonist use, total amount of gonadotrophins in IU per woman who started an IVF/ICSI cycle, clinical pregnancy, live birth, cumulative live birth following fresh and cryocycles and funding per included study. An overview of study characteristics is shown in [Table I](#TB1){ref-type="table"}. Some trials reported the total number of ampoules used. We transformed this data into the amount of gonadotrophins in IU. Our primary outcome was the total amount of gonadotrophins in IU per woman who started an IVF/ICSI cycle required per live birth. Secondary outcomes were the total amount of gonadotrophins in IU per woman who started IVF/ICSI cycle, clinical pregnancy, cumulative live birth following fresh and cryocycles and oocytes retrieved.

###### 

Characteristics of studies in a systematic review and meta-analysis of gonadotrophin required for a live birth.

  **Study**   **Couples (*n*)**   **Age women (yrs)**   **Previous cycles (*n*)**               **Intervention**   **Control**   **Starting dose (IU)**    **Downregulation protocol**   **IVF/ICSI**   **Embryo transfers (*N*)**   **Funding**
  ----------- ------------------- --------------------- --------------------------------------- ------------------ ------------- ------------------------- ----------------------------- -------------- ---------------------------- --------------
  [@ref1])    401                 26--38                \<3 Oocyte retrievals                   rFSH               HP-FSH        225                       Long GnRH agonist             IVF/ICSI       1--3                         No
  [@ref3])    731                 21--37                \<4                                     rFSH               HP-hMG        225                       Long GnRH agonist             IVF            1--2                         Ferring
  [@ref6])    150                 18--39                \<3                                     rFSH               HP-FSH        225                       Long GnRH agonist             IVF/ICSI       1--                          IBSA
  [@ref7])    152                 18--39                \<3                                     rFSH               HP-FSH        300                       Long GnRH agonist             IVF/ICSI       1--3                         IBSA
  [@ref9])    235                 18--38                \<4 ART cycles                          rFSH               HP-FSH        150                       Long GnRH agonist             IVF/ICSI       2--3                         Serono
  [@ref10])   280                 18--37                0                                       rFSH               HP-hMG        225                       Antagonist                    IVF/ICSI       1--3                         No
  [@ref12])   749                 21--34                \<2 Cos cycles                          rFSH               HP-hMG        150                       Antagonist                    ICSI           Max 1                        Ferring
  [@ref14])   177                 18--39                No inclusion criteria                   rFSH               HP-FSH        250                       Long GnRH agonist             IVF            Max 4                        Ferring
  [@ref13])   120                 18--39                No inclusion criteria                   rFSH               HP-FSH        225                       Long GnRH agonist             IVF            Max 4                        Ferring
  [@ref15])   781                 23--26                \<4 ART cycles                          rFSH               HP-hMG        225                       Long GnRH agonist             IVF/ICSI       1--3                         Ferring
  [@ref16])   141                 29--45                No ovarian response in previous cycle   rFSH               HP-FSH        300                       No                            IVF/ICSI       Max 3                        No
  [@ref17])   120                 \<37                  Not reported                            rFSH               HP-FSH        150                       Long GnRH agonist             ICSI           Max 4                        Serono
  [@ref18])   278                 18--38                \<4 ART cycles                          rFSH               HP-FSH        150                       Long GnRH agonist             IVF            2--5                         Serono
  [@ref19])   100                 \<40                  0                                       rFSH               HP-FSH        225                       Long GnRH agonist             IVF            Max 3                        Not reported
  [@ref21])   79                  \>35                  Not reported                            rFSH               HP-FSH        225                       No                            IVF/ICSI       2--3                         Not reported
  [@ref22])   47                  \<37                  \<4 IVF cycles                          rFSH               FSH-HP        150 rFSH and 225 FSH-HP   Long GnRH agonist             IVF            Max 3                        Not reported
  [@ref23])   506                 18--39                0                                       rFSH               HP-hMG        225                       Long GnRH agonist             IVF            1--2                         Ferring
  [@ref24])   169                 18--39                \<3                                     rFSH               HP-FSH        150 rFSH and 225 FSH-HP   Long GnRH agonist             IVF            Max 3                        Organon
  [@ref25])   88                  18--38                Not reported                            rFSH               HP-FSH        100 rFSH and 150 FSH-HP   Short GnRH agonist            IVF            Max 3                        No
  [@ref26])   100                 18--37                \<3                                     rFSH               HP-hMG        150                       Long GnRH agonist             IVF/ICSI       1--2                         No
  [@ref27])   168                 18--38                0 ART cycles                            rFSH               HP-FSH        150                       Long GnRH agonist             IVF/ICSI       1--2                         Serono
  [@ref29])   508                 \>37                  \<3                                     rFSH               HP-FSH        300                       Long GnRH agonist             IVF/ICSI       Max 3                        No
  [@ref32])   257                 \>39                  No inclusion criteria                   rFSH               HP-FSH        300                       Long GnRH agonist             IVF            Max 3                        No
  [@ref33])   110                 Not reported          Not reported                            rFSH               HP-FSH        Not reported              Long GnRH agonist             IVF            Max 3                        Not reported
  [@ref34])   114                 Not reported          Not reported                            rFSH               HP-FSH        150 rFSH and 225 FSH-HP   Long GnRH agonist             IVF            Not reported                 Serono
  [@ref38])   496                 18--38                \<3 ART cycles                          rFSH               HP-FSH        150                       Long GnRH agonist             IVF/ICSI       Max 3                        Serono
  [@ref39])   267                 18--38                0                                       rFSH               HP-FSH        225                       Long GnRH agonist             IVF/ICSI       Max 3                        No
  [@ref43])   127                 \>34                  0                                       rFSH               HP-hMG        225                       Short GnRH agonist            IVF/ICSI       2--3                         No

rFSH: recombinant FSH, HP: highly purified.

In our protocol (Prospero CRD42016038238) we intended to report duration of stimulation. Although we did evaluate this outcome we decided not to present this analysis, since some days more or less stimulation time does not represent resource use, while total amount of gonadotropins used does.

![**Flow diagram showing the search for articles for inclusion in the systematic review and meta-analysis.** hMG = human menopausal gonadotropin. P-FSH = purified follicle-stimulating hormone.](hoz008f1){#f1}

![**Methodological quality summary: authors' judgments about each methodological quality item for each study included.** Red dots: high risk of bias, yellow dots: unclear risk of bias, green dots: low risk of bias.](hoz008f2){#f2}

Assessment of study quality {#sec17}
---------------------------

To check the quality of the article we used the risk of bias tool created by the Cochrane Collaboration (*Cochrane Handbook*). We looked at the following six domains: randomization sequence generation, allocation concealment, performance and detection bias, completeness of outcome data, selective outcome reporting and other potential sources. Risk of bias per study was expressed in the methodological quality graph as colored dots, with red dots meaning high risk of bias, yellow meaning unclear risk of bias and green meaning low risk of bias. Pooled evidence was scored using Grade Profiler 3.6.1 (GRADEpro Guideline Development Tool \[Software\]; McMaster University, 2015 \[developed by Evidence Prime, Inc.\]; available from [gradepro.org](https://gradepro.org/cite/gradepro.org).) as very low, low, moderate or high.

Statistical analysis {#sec18}
--------------------

We retrieved for each individual study means and SD for the total amount of gonadotrophins per woman who started an IVF/ICSI cycle. We tried to retrieve these data and data on clinical pregnancy, live birth and cumulative live birth following fresh and cryocycles per woman treated with gonadotrophins. The outcomes were summarized by calculating the individual and pooled mean difference (MD) or relative risk (RR) with 95% CI for rFSH versus HP-hMG and rFSH versus HP-FSH. We used the Review Manager software (Review Manager \[RevMan\] Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) to perform these meta-analyses. Presence of heterogeneity was assessed by the *I*^2^ statistic. An *I*^2^ \>50% was taken to indicate substantial heterogeneity. We calculated the mean amount of gonadotrophin used per clinical pregnancy per woman in STATA 14.2 (StataCorp. 2015. *Stata Statistical Software: Release 14*. College Station, TX, USA: StataCorp LP). We estimated the MD and 95% CI in amount of gonadotrophins per extra clinical pregnancy, per extra live birth and per extra cumulative live birth achieved for the two gonadotrophin comparisons by bootstrapping techniques using Metafor ([www.metaforproject.org](http://www.metaforproject.org)) in R version 3.3.1. An extra, not pre-planned, analysis was done for oocytes retrieved and amount of gonadotrophin per extra oocyte retrieved.

Results {#sec19}
=======

Search {#sec20}
------

We identified 362 records and hand searching resulted in another 11 records. After we removed the duplications, there were 348 records to screen for title and abstract. We excluded 302 records based on the inclusion and exclusion criteria*.* We assessed a total of 46 articles for eligibility by reading the full text after which we excluded another 18 studies expressing 19 comparisons. A summary of the search is presented in a flow diagram ([Fig. 1](#f1){ref-type="fig"}).

Included studies {#sec21}
----------------

We included the 28 studies that met all selection criteria in the review. The total number of women was 7553. Seven studies compared rFSH with HP-hMG (*n* = 3397) and all provided data on the amount of gonadotrophin used. In total, 3220 women (95%) actually had started gonadotrophin treatment. Twenty-one studies compared rFSH with HP-FSH (*n* = 4156), but only 17 (*n* = 3775) provided data on amount of gonadotrophin used. In total, 3629 women (96%) actually had started gonadotrophin treatment. The studies varied in terms of female age, previous ART cycles, starting dose, downregulation protocol, fertilization method, number of embryo transfers and funding. The characteristics of each study can be found in [Table I](#TB1){ref-type="table"}.

Assessment of study quality {#sec22}
---------------------------

The results of the assessment of the risks of bias using the Cochrane tool are summarized in [Figs 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}. The quality of the studies varied between low and high. Older studies performed before 2000 were more likely to be of lower quality. Five studies were only available as an abstract, all comparing rFSH versus HP-FSH ([@ref16]; [@ref19]; [@ref21]; [@ref22]; [@ref34]). We considered these five studies to be of low quality, mainly due to incomplete outcomes, reporting bias and uncertainty about selection bias and other forms of bias.

![**Methodological quality graph: authors' judgments about each methodological quality item presented as percentages across all studies included**.](hoz008f3){#f3}

![**Meta-analyses comparing total amount of gonadotrophins used (IU) per woman that started an IVF/ICSI cycle.** (**A**) Comparing recombinant FSH (rFSH) with urinary-derived highly purified hMG (HP-hMG). (**B**) Comparing rFSH with highly purified FSH (HP-FSH).](hoz008f4){#f4}

![**Meta-analyses comparing rFSH with HP-hMG.** (**A**) Comparing clinical pregnancy. (**B**) Comparing live birth. (**C**) Comparing cumulative live birth.](hoz008f5){#f5}

In two studies we could not determine whether the data were intention-to-treat or not ([@ref19]; [@ref29]). None of the trials used double blinding. Although double blinding is unlikely to have impact on pregnancy outcomes, it might have biased the outcome gonadotrophin amount.

Outcomes {#sec23}
--------

### Amount of gonadotrophins per woman that started IVF/ICSI cycle {#sec24}

Of the seven trials comparing rFSH with HP-hMG, three trials found no evidence of a difference in the amount of gonadotrophins, one found that more rFSH was required and three trials found that less rFSH was required. Pooling the data, we found no evidence of a difference in the amount of gonadotrophins (seven studies; *N* = 3220; MD, −37 IU; 95% CI, −115 to 41; *I*^2^ = 68%; low quality of evidence) ([Fig. 4a](#f4){ref-type="fig"}).

Of the 17 trials comparing rFSH with HP-FSH, seven trials found no evidence of a difference in the amount of gonadotrophins, three found that more rFSH was required and seven found that less rFSH was required. Pooling the data, we found no evidence of a difference in the amount of gonadotrophins (17 studies; *N* = 3629; MD −31 IU; 95% CI, −290 to 228; *I*^2^ = 97%; low quality of evidence) ([Fig. 4b](#f4){ref-type="fig"}). For both comparisons there was severe statistical heterogeneity.

### Pregnancy outcomes {#sec25}

Of the seven trials comparing rFSH and HP-hMG, all trials had data on clinical pregnancy and live birth rate and three trials (*N* = 2109) had data on cumulative live births following fresh and cryo-embryo transfers ([Fig. 5](#f5){ref-type="fig"}).

We found a slightly lower clinical pregnancy rate and live birth rate in the rFSH-treated women than in the HP-hMG-treated women (seven studies, *N*= 3397. Clinical pregnancy: RR, 0.90; 95% CI, 0.81--1.00. Live birth: RR, 0.88; 95% CI, 0.78--0.99; high quality of evidence). We found insufficient evidence of a difference in cumulative live birth rate (three studies, *N* = 2109. Cumulative live birth: RR, 0.91; 95% CI, 0.80--1.04). There was no indication of heterogeneity for these outcomes across studies (*I*^2^ = 0%, high quality of evidence).

Of the 21 trials comparing rFSH and HP-FSH, all trials had data on clinical pregnancy rate and 12 trials had data on live birth rate ([Fig. 6](#f6){ref-type="fig"}). One trial had data on cumulative ongoing pregnancies following frozen-thawed embryo transfers ([@ref36]), but no trials had data on cumulative live birth rate.

![**Meta-analyses comparing rFSH with HP-FSH.** (**A**) Comparing clinical pregnancy. (**B**) Comparing live birth.](hoz008f6){#f6}

We found little or no difference in clinical pregnancy rate nor in live birth rate in the rFSH-treated women compared to HP-FSH-treated women (21 studies, *N* = 4165. Clinical pregnancy: RR, 1.03; 95% CI, 0.94--1.13. Twelve studies, *N* = 2458. Live birth: RR, 1.03; 95% CI, 0.90--1.18). There was no indication of heterogeneity across studies (*I*^2^ = 0%, high quality of evidence).

### Required amount to reach a clinical pregnancy {#sec26}

Comparingv rFSH with HP-hMG, we found that the required amount to achieve a clinical pregnancy was 7168 IU (95% CI, 5007 to 9330) for rFSH and 5774 IU (95% CI, 4061 to 7488) for HP-hMG. The difference in mean gonadotrophin amount per extra clinical pregnancy was 720 IU (95% CI, −29 to 1470) for rFSH versus HP-hMG ([Fig. 7](#f7){ref-type="fig"}).

![**Forest plot showing the difference in gonadotrophin use per extra live birth and clinical pregnancy**.](hoz008f7){#f7}

Comparing rFSH with HP-FSH, we found that the required amount to achieve a clinical pregnancy was 8017 IU (95% CI, 6714 to 9320) for rFSH and 9079 IU (95% CI, 7297 to 10861) for HP-FSH. The difference in mean gonadotrophin amount per extra clinical pregnancy was −380 IU (95% CI, −1778 to 1017) for rFSH versus HP-FSH ([Fig. 7](#f7){ref-type="fig"}).

### Required amount to reach a live birth {#sec27}

Comparing rFSH with HP-hMG, we found that the required amount to achieve a live birth was 8222 IU (95% CI, 5743 to 10 703) for rFSH and 6548 IU (95% CI, 4605 to 8491) for HP-hMG. The difference in mean gonadotrophin amount per extra live birth was 789 IU (95% CI, −9.5 to 1570) for rFSH versus HP-hMG ([Fig. 7](#f7){ref-type="fig"}). In the three trials with data on cumulative live births the difference in mean gonadotrophin amount per extra live birth was 310 IU (95% CI, **−**158 to 778) for rFSH versus HP-hMG.

Comparing rFSH with HP-FSH, we found that the required amount to achieve a live birth was 9880 IU (95% CI, 8080 to 11489) for rFSH and 11 076 IU (95% CI, 8583 to 13924) for HP-FSH. The difference in mean gonadotrophin amount per extra live birth was −365 IU (95% CI, −2675 to 1945) for rFSH versus HP-FSH ([Fig. 7](#f7){ref-type="fig"}).

### Required amount for one more oocyte {#sec28}

Of the seven trials comparing rFSH and HP-hMG, all trials had data on the number of oocytes retrieved. Of the 21 trials comparing rFSH and HP-FSH, all trials had data on the number of oocytes retrieved. MD in number of oocytes retrieved was 1.83 (95% CI, 1.20 to 2.64; *N* = 3397; *I*^2^ = 70%; low quality evidence) for rFSH versus HP-HMG and was −0.57 (95% CI, −0.20 to 1.33; *N* = 2458; *I*^2^ = 80%; low quality evidence) for rFSH versus HP-FSH.

Comparing rFSH with HP-HMG, we found that the required amount per oocyte retrieved was 198 IU (95% CI, --38 to 433) for rFSH and 230 IU (95% CI, 107 to 352) for HP-HMG. The estimated difference in mean gonadotrophin amount per extra oocyte was --50 IU (95% CI, --276 to 226) for rFSH versus HP-FSH.

Comparing rFSH with HP-FSH, we found that the required amount per oocyte retrieved was 260 IU (95% CI, 17 to 503) for rFSH and 286 IU (95% CI, 153 to 418) for HP-FSH. The estimated difference in mean gonadotrophin amount per oocyte was −18 IU (95% CI, −322 to 304) for rFSH versus HP-FSH.

In all comparisons both oocyte number and amount of gonadotrophin differed across studies, creating severe statistical heterogeneity. This limits the external validity of the estimated required amount of gonadotrophin for one more oocyte presented here.

Discussion {#sec29}
==========

In this systematic review and meta-analysis we evaluated the evidence on the total amount of gonadotrophins required to reach a live birth after ovarian stimulation with rFSH in comparison to HP-hMG or HP-FSH in couples undergoing IVF or ICSI treatment. We found no evidence of a difference in amount of gonadotrophins per woman who started an IVF/ICSI cycle and per live birth between rFSH and HP-hMG or HP-FSH.

The main strength of our study is that we were able to collect data for 7553 women from studies with a strong design. Also, the results are applicable to a general IVF/ICSI population and are important from a social-economic perspective.

A limitation lies in the severe clinical heterogeneity in mean total amount of gonadotrophins used across individual studies. Study year and country could partly explain this heterogeneity. Older studies often used higher starting doses.

Not all studies reported early drop outs, and for those studies we can thus not be certain that all women started gonadotrophin treatment. This might have affected the averaged total amount of gonadotrophins.

A further limitation of our review is that we did not evaluate potential differences in patient characteristics such as female age and indication for IVF. These factors could influence resource use. To take these differences into account an individual participant data meta-analysis would be necessary.

In our meta-analysis we focused on the total amount of gonadotrophins required to reach a clinical pregnancy. Previous meta-analyses focused on the effectiveness and safety of the different types of gonadotrophin ([@ref11]; [@ref2]; [@ref41]; [@ref20]). These meta-analyses suggested that HP-hMG results in slightly more clinical pregnancies and live births than rFSH, possibly due to the LH activity in HP-hMG, but the relation to the required gonadotrophin amount per live birth was not studied.

We consider the required gonadotrophin amount per clinical pregnancy or per live birth to be representative of the biopotency of a gonadotrophin. A more biopotent product would require a lower total dose and less stimulation days in comparison to a less biopotent product. In general, basic FSH isoforms, such as rFSH, have a higher receptor affinity *in vitro* compared to more acid isoforms, such as HP-hMG and HP-FSH, but more acid isoforms have a longer plasma half-life compared to basic FSH isoforms. There has been much discussion on the presumed differences in biopotency of the various gonadotrophins related to isoform composition and acidity. Some studies describe that it is unknown whether these differences influence biopotency ([@ref37]; [@ref40]), while others suggest that in view of the higher biopotency *in vitro,* rFSH might also be more biopotent *in vivo (*[@ref8]; [@ref5]; [@ref4]*)*, and one study suggests that, because of the longer plasma half-lives, more acid isoforms have an higher *in vivo* bioactivity ([@ref42]).

It can be argued that gonadotrophin amount per oocyte would better represent biopotency. Although not pre-defined, we added this outcome to our analysis and found insufficient evidence of a difference between rFSH and HP-HMG, and rFSH and HP-FSH. This analysis was hampered by the heterogeneity in the data.

Our results suggest that, although rFSH, HP-hMG and HP-FSH differ in isoform composition and acidity, as well as in LH activity, these gonadotrophins have a comparable biopotency.

We conclude that the differences in required amount of gonadotrophin to reach a live birth between rFSH, HP-hMG and HP-FSH are small. Decision-making should thus be based on convenience, availability, actual costs and patient preferences.
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